Automated Cell-free Protein Synthesis for Distributed Biomanufacturing

Le résumé fourni par la source

ABSTRACT Recombinant proteins are fundamental to modern medicine, enabling research, diagnostics, and drug discovery, yet their access is often restricted by centralized manufacturing and cold-chain distribution. Decentralized, on-site biomanufacturing can enable research, provide resilience, and advance personalized medicine. Here, we introduce MANGO (MANufacturing on the GO), a purpose-built, open-source device designed for automated, benchtop cell-free protein synthesis and purification. Computer-controlled synthesis and purification are mediated through biomedical-grade pumps, valves, and a microchannel manifold, enabling rapid protein production directly at the point-of-use. To demonstrate MANGO’s utility, we produced and validated a diverse range of proteins, including nanobodies against SARS-CoV-2 and TNF, cloning enzymes, and diagnostic enzymes, with performance equivalent to their commercial counterparts. We further deployed MANGO in Brazil and Colombia to support patient trials for SARS-CoV-2 and dengue virus diagnostics. These results establish MANGO as a low-cost, portable platform that can democratize access to bioreagents in both high- and low-resource settings and, ultimately, expand participation in the bioeconomy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.